Tell me about aztr and when should I buy it

**Azitra, Inc. (AZTR) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products**. Here's an analysis to help you decide when to buy the stock: 1. **Product Pipeline and Clinical Trials**: Azitra has a promising product pipeline, including ATR-12 for Netherton syndrome and ATR-04 for EGFR inhibitor-associated rash. The company is set to begin a first-in-human trial of ATR-12 in 2023. Recent preclinical data presented by Azitra suggest that ATR-12 shows potential for treating Netherton syndrome by significantly reducing IL-36γ, a pro-inflammatory cytokine. 2. **Industry Position**: Azitra operates within the biotechnology industry, which is known for its potential for high growth. |Ticker|Name|GICS Industry|Date|code|market_code| |---|---|---|---|---|---| |AZTR.A|Azitra|Biotechnology||AZTR|170| 3. **Stock Performance**: The stock has experienced significant volatility, with a high weekly volatility of 81.40%. The stock's recent price movement may indicate short-term overvaluation, but long-term investors might see potential in the company's pipeline and industry position. 4. **Technical Indicators**: The stock's RSI (Relative Strength Index) is at 39.8, which is neither overbought nor oversold. The MACD (Moving Average Convergence Divergence) is at 0.17, indicating a potential upward momentum. The KDJ (Stochastic Oscillator) is at 4.3, suggesting an oversold condition. |Ticker|Name|RSI|Date|code|market_code| |---|---|---|---|---|---| |AZTR.A|Azitra|39.8007|20240724|AZTR|170| |Ticker|Name|KDJ|Date|code|market_code| |---|---|---|---|---|---| |AZTR.A|Azitra|4.3028|20240724|AZTR|170| 5. **Market Sentiment**: The company's recent announcements of preclinical data and presentations at industry conferences indicate positive developments. 6. **Valuation**: Azitra's focus on precision dermatology and its innovative approach using genetically engineered bacteria could justify a higher valuation. However, investors should consider the company's stage of development and the potential risks associated with clinical trials and regulatory approvals. **Conclusion**: Given the company's promising pipeline, industry position, and recent positive developments, Azitra could be a good long-term investment option. However, short-term investors should be cautious due to the stock's high volatility. For a long-term buy, consider a gradual approach, buying over a series of days or weeks to average the purchase price and reduce the impact of short-term volatility.